Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial

n the EMN01 trial, the addition of an alkylator (melphalan or cyclophosphamide) to lenalidomide-steroid induction therapy was prospectively evaluated in transplant-ineligible patients with multiple myeloma. After induction, patients were randomly assigned to maintenance treatment with lenalidomide a...

Descripción completa

Detalles Bibliográficos
Autores principales: Bringhen, Sara, D’Agostino, Mattia, Paris, Laura, Ballanti, Stelvio, Pescosta, Norbert, Spada, Stefano, Pezzatti, Sara, Grasso, Mariella, Rota-Scalabrini, Delia, De Rosa, Luca, Pavone, Vincenzo, Gazzera, Giulia, Aquino, Sara, Poggiu, Marco, Santoro, Armando, Gentile, Massimo, Baldini, Luca, Petrucci, Maria Teresa, Tosi, Patrizia, Marasca, Roberto, Cellini, Claudia, Palumbo, Antonio, Falco, Patrizia, Hájek, Roman, Boccadoro, Mario, Larocca, Alessandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327625/
https://www.ncbi.nlm.nih.gov/pubmed/31582542
http://dx.doi.org/10.3324/haematol.2019.226407

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327625/
https://www.ncbi.nlm.nih.gov/pubmed/31582542
http://dx.doi.org/10.3324/haematol.2019.226407

Ejemplares similares